Elango Anitha, Kannan Iyanar, Ravichandar Ramya, Kumaravelu Punnagai
Department of Pharmacology, Panimalar Medical College Hospital and Research Institute, Chennai.
Department of Microbiology, Tagore Medical College and Hospital, Chennai.
Bioinformation. 2024 Jul 31;20(7):711-718. doi: 10.6026/973206300200711. eCollection 2024.
Estrogen receptor-α (ER- α) is a principal endocrine regulatory protein in breast cancer. The progression of ER-α positive breast cancer is slowed by selective estrogen receptor modulators such as Tamoxifen. But, long term therapy with Tamoxifen leads to resistance. Therefore, it is of interest to document the Molecular docking and pharmacokinetic analysis of imeglimin derivatives with ER-alpha. Among the 166 derivatives of Imeglimin, only five derivatives were shortlisted after toxicity testing. The selected derivatives showed good binding affinity with favorable pharmacokinetic profiles. The selected compounds of Imeglimin were found to possess excellent anticancer potential and could be considered as novel, cost-effective anticancer agents effective against ER positive breast cancer for further investigation.
雌激素受体-α（ER-α）是乳腺癌中的一种主要内分泌调节蛋白。他莫昔芬等选择性雌激素受体调节剂可减缓ER-α阳性乳腺癌的进展。但是，长期使用他莫昔芬治疗会导致耐药性。因此，记录依美格鲁明衍生物与ER-α的分子对接和药代动力学分析很有意义。在依美格鲁明的166种衍生物中，经过毒性测试后仅筛选出5种衍生物。所选衍生物表现出良好的结合亲和力和有利的药代动力学特征。发现依美格鲁明的所选化合物具有出色的抗癌潜力，可被视为对ER阳性乳腺癌有效的新型、经济高效的抗癌剂，以供进一步研究。
